158
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma

, , , , , ORCID Icon, & show all
Pages 131-143 | Received 18 Oct 2023, Accepted 11 Jan 2024, Published online: 16 Jan 2024

Figures & data

Table 1 The Baseline Characteristics of the Subjects Included in This Study

Figure 1 Serum AKR1B10 levels in various groups.

Abbreviations: AKR1B10, aldo-keto reductase family 1 member B10; HCC, hepatocellular carcinoma; HC, healthy controls; BLD, benign liver diseases; OC, other cancers.
Figure 1 Serum AKR1B10 levels in various groups.

Table 2 Association Between AKR1B10 Expression and the Clinicopathological Parameters of HCC Patients

Figure 2 Correlation of serum AKR1B10 with other laboratory indicators.

Abbreviations: AKR1B10, aldo-keto reductase family 1 member B10; ALT, alanine transaminase; TP, total protein; ALB, albumin; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; AST, aspartate transaminase; LD, lactic dehydrogenase; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9; Tbil, total bilirubin; Dbil, direct bilirubin; TC, total cholesterol; TG, total triglycerides.
Figure 2 Correlation of serum AKR1B10 with other laboratory indicators.

Table 3 Diagnostic Parameters of AKR1B10, AFP, CEA, and CA19-9 to Distinguish HCC Group from Control Groups

Figure 3 Diagnostic performance of serum AKR1B10, AFP, CEA, and CA19-9 in HCC. (AD) ROC curves of serum AKR1B10, AFP, CEA and CA19-9 differentiating HCC from HC, BLD, OC, and AC groups; (EH) ROC curves of combining serum AKR1B10 with AFP differentiating HCC from HC, BLD, OC, and AC groups.

Abbreviations: HCC, hepatocellular carcinoma; HC, healthy controls; BLD, benign liver diseases; OC, other cancers; AC, all controls; AKR1B10, aldo-keto reductase family 1 member B10; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9.
Figure 3 Diagnostic performance of serum AKR1B10, AFP, CEA, and CA19-9 in HCC. (A–D) ROC curves of serum AKR1B10, AFP, CEA and CA19-9 differentiating HCC from HC, BLD, OC, and AC groups; (E–H) ROC curves of combining serum AKR1B10 with AFP differentiating HCC from HC, BLD, OC, and AC groups.

Table 4 Positive Rates of Serum AKR1B10, AFP, CEA, and CA19-9 in HCC Patients

Table 5 Diagnostic Parameters of Serum AKR1B10 to Distinguish AFP-Negative HCC Group from Control Groups

Figure 4 Diagnostic performance of serum AKR1B10 in AFP-negative HCC. (AD) ROC curves of serum AKR1B10 differentiating AFP-negative HCC from HC, BLD, OC, and AC groups.

Abbreviations: HCC, hepatocellular carcinoma; HC, healthy controls; BLD, benign liver diseases; OC, other cancers; AC, all controls; AKR1B10, aldo-keto reductase family 1 member B10.
Figure 4 Diagnostic performance of serum AKR1B10 in AFP-negative HCC. (A–D) ROC curves of serum AKR1B10 differentiating AFP-negative HCC from HC, BLD, OC, and AC groups.

Figure 5 Changes in serum AKR1B10 levels before and after surgery. (A) Serum AKR1B10 levels in HCC patients who underwent resection at pre-surgery, 1–2 days after surgery, and 3–4 days after surgery; (B) Positive proportions of serum AKR1B10 in HCC patients who underwent resection at pre-surgery, 1–2 days after surgery, and 3–4 days after surgery.

Abbreviations: T0, pre-surgery; T1, 1–2 days after surgery; T2, 3–4 days after surgery; AKR1B10, aldo-keto reductase family 1 member B10.
Figure 5 Changes in serum AKR1B10 levels before and after surgery. (A) Serum AKR1B10 levels in HCC patients who underwent resection at pre-surgery, 1–2 days after surgery, and 3–4 days after surgery; (B) Positive proportions of serum AKR1B10 in HCC patients who underwent resection at pre-surgery, 1–2 days after surgery, and 3–4 days after surgery.